focus -WSS

focus

author：knowledge 2025-10-01 00:06:41 - browse：53

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： A look at other Americans who have crossed into North Korea over the years

WSS

Flagship, Pfizer team up in deal worth up to $7 billion

IVG is promising — but it won’t replace IVF quite yet

Medicare innovation center doesn’t save money, experts say

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

The Karikó problem: Lessons for funding basic research

Congress extends some pandemic preparedness programs

hotspot

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

BioMarin wins approval for gene therapy to treat hemophilia A

Congress extends some pandemic preparedness programs

As demand for Covid shots wanes, Moderna seeks its next success

CDC picks Alphabet's Verily for wasterwater surveillance contract

Moonlake's readout produced a cash windfall. Risks remain

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

United colonoscopy coverage change 'may cost lives,' doctors say

Phoenix breaks record with 19 consecutive days above 110 degrees Fahrenheit

Cancer drug shortages should be causing more outrage

Health insurers' Q3 question: how much care are people getting?

hotspot

What will Novo Nordisk's VC do with its influx of cash?

House passes resolution saying Israel isn't a 'racist or apartheid state'

Idaho college killings: Prosecutors dispute DNA could have been planted at murder scene

Asa Hutchinson previews new plan to reform federal law enforcement if elected in 2024

Stop Congress from blocking public access to science

What we owe ALS patients — and why one company fell short

hotspot

hotspot

explore

knowledge